New Risk • Aug 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (CA$110k revenue, or US$79k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€26.6m market cap, or US$30.7m). Annuncio • Jul 17
Onco-Innovations Limited Initiates ADME Studies for ONC010 Onco-Innovations Limited announced the initiation of key absorption, distribution, metabolism and excretion ("ADME") studies for ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The studies are designed to characterize ONC010's pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program. The initial ADME work is focused on metabolism of the active pharmaceutical ingredient (API) in the ONC010 lead drug candidate. These data are intended to support the Company's broader development strategy by informing manufacturing activities, formulation optimization, toxicology studies and future clinical translation. The studies are expected to contribute to the growing body of preclinical evidence supporting the continued advancement of ONC010 toward clinical evaluation. The ADME studies form part of Onco-Innovations’ broader IND-enabling development program for ONC010, which also includes manufacturing, formulation, safety and regulatory activities intended to support future clinical evaluation. ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies. Annuncio • Jul 11
Onco-Innovations Completes Analytical Reference Standard Preparation Program For ONC010’s API Onco-Innovations announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting the Company's lead oncology program, ONC010 (the “PNKP Inhibitor Technology”). The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational tools within pharmaceutical development and quality control systems, enabling consistent evaluation of identity, purity, potency, stability, impurity profiles and batch-to-batch comparability throughout the development lifecycle. Completion of the program establishes an important analytical benchmark for future manufacturing campaigns and supports the Company's broader strategy of building a comprehensive quality infrastructure for ONC010. The completion of the reference standard program follows several recent chemistry, manufacturing and controls (CMC) achievements within the ONC010 development program, including successful precursor scale-up activities, API manufacturing advancements, analytical method development, chiral purity testing and continued progress toward manufacturing scale-up and regulatory readiness. The reference standard preparation program forms part of a broader analytical development strategy currently underway at Onco-Innovations. Additional activities include analytical method qualification, stability-indicating methodologies, residual solvent testing, impurity profiling, forced degradation studies, formulation characterization and quality control system development. ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies. New Risk • Jul 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.5m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (CA$155k revenue, or US$109k). Minor Risk Market cap is less than US$100m (€29.0m market cap, or US$33.2m). Annuncio • Jun 24
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for Onc010 Onco-Innovations entered into a services agreement with Nanosoft Polymers, a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. The work is intended to strengthen the manufacturing and formulation foundation of ONC010 as research and development efforts advance through IND-enabling development and preparation for future clinical studies. Nanosoft brings extensive experience in polymer synthesis, nanoparticle drug delivery systems, process optimization, analytical characterization, and scalable manufacturing approaches for therapeutic applications. The program will focus on establishing a robust, reproducible, and scalable polymer manufacturing process while enhancing analytical methods and quality controls necessary to support future manufacturing, regulatory, and clinical development activities. Nanosoft will also support process scale-up and technology transfer initiatives designed to facilitate future GMP manufacturing and commercial development opportunities. Nanosoft's work will complement ongoing chemistry, manufacturing and controls activities being conducted by Dalton Pharma Services and preclinical development activities being conducted by Nucro-Technics. Together, these organizations form a growing development ecosystem supporting the advancement of ONC010 toward First-in-Human clinical evaluation. Annuncio • Jun 11
Onco-Innovations Initiates API Process Development and Intermediate Scale-Up Program for Proprietary PNKP Inhibitor Technology Onco-Innovations Limited announced the initiation of process development and intermediate scale-up activities for A83B4C63, the Company’s active pharmaceutical ingredient (API) in the Company's proprietary drug candidate, ONC010 (the “PNKP Inhibitor Technology”). This milestone marks an important step in advancing the Company’s chemistry, manufacturing, and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for First-in-Human clinical evaluation. The program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The process development effort will be conducted in collaboration with Dalton Pharma Services, a GMP-compliant contract development and manufacturing organization, with additional technical integration support across the Company’s broader development ecosystem. The initiative is designed to ensure that the API manufacturing process is robust, scalable and aligned with future GMP production requirements. By advancing intermediate scale-up, Onco-Innovations aims to establish consistent production of high-purity material suitable for continued preclinical development, analytical validation and eventual clinical supply. The work will also support refinement of critical quality attributes, including impurity profiles and batch reproducibility, which are essential for regulatory readiness. Annuncio • Jun 03
Onco-Innovations Advances 1Kg Scale-Up of B4 Precursor Supporting Onc010 Manufacturing and Clinical Development Program Onco-Innovations Limited announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component supporting the development of ONC010, the Company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) Inhibitor Technology. The milestone was achieved through the Company’s ongoing chemistry, manufacturing and controls (CMC) collaboration with Dalton Pharma Services and represents an important step in scaling the manufacturing process required to support future formulation development, engineering batches, GMP production and planned clinical studies. B4 is a critical precursor used in the synthesis pathway for ONC010 and forms an essential component of the Company’s broader manufacturing strategy. Recent scale-up activities resulted in the successful production and isolation of approximately 952 grams of B4 material, representing a meaningful increase in manufacturing scale while maintaining quality standards necessary for continued development activities. The B4 scale-up milestone forms part of a broader integrated manufacturing program that includes precursor synthesis, Active Pharmaceutical Ingredient (API) production, polymer development, nanoparticle formulation, analytical characterization and future GMP manufacturing activities. The Company's manufacturing ecosystem currently includes Dalton Pharma Services and Nucro-Technics, each contributing specialized expertise across critical development workstreams. Manufacturing readiness is a fundamental component of successful clinical translation. The advancement of kilogram-scale precursor production strengthens the foundation of the ONC010 program and supports the Company's broader objective of delivering a clinically viable and scalable therapeutic candidate. As we continue progressing through IND-enabling activities, these manufacturing achievements contribute directly to reducing development risk and supporting future regulatory readiness. ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies. Board Change • May 20
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Independent Director Maximilian Justus is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Jan 25
Onco-Innovations Limited announced that it expects to receive CAD 2 million in funding Onco-Innovations Limited announced a non-brokered private placement of up to 2,272,727 units at a price of CAD 0.88 per unit for aggregate gross proceeds of up to CAD 1,999,999.76 on January 23, 2026. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.10 for a period of 36 months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm's-length third party as an administrative fee for its assistance with the private placement. In connection with the private placement, the company may pay finders' fees and/or issue finders' warrants on the same terms as the warrants to eligible parties which have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to the private placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. Board Change • Dec 30
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Independent Director Maximilian Justus is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Nov 22
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies Onco-Innovations Limited announced that its manufacturing partner, Dalton Pharma Services ("Dalton"), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company's proprietary PNKP Inhibitor Technology. This phase of work is designed to refine and scale the synthesis process under non-GMP conditions as part of Onco's ongoing manufacturing development program, supporting future clinical material production. Building on the manufacturing activities previously initiated by Dalton for preclinical testing material, the Company has now advanced to the optimization and intermediate-scale production (for research purposes) of A83B4C63. This next phase focuses on process scale-up and analytical method qualification, which is intended to ensure a robust, reproducible, and scalable manufacturing process suitable for future GMP production and subsequent manufacturing of clinical material to support Onco's IND enabling and Phase 1 studies. The work will be performed using dedicated pilot-scale equipment at Dalton's FDA- and Health Canada-approved facility in Toronto, Canada. As part of this optimization phase, Dalton will conduct intermediary scale-up batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4 to evaluate reaction performance under scale-up conditions in preparation for pre-clinical production of A 83B4C63. The A83B4C63 active pharmaceutical ingredient (API) will be used to support the development of Onco's encapsulated nanoparticle micelle formulation, which is designed with the goal of enhancing tumor-targeted delivery of the PNKP inhibitor, and with the ultimate goal of potentially improving therapeutic efficacy in cancer treatment. The manufacturing program also includes comprehensive analytical method development and stability testing conducted in accordance with International Council for Harmonisation (ICH) guidelines, as well as a formal safety and risk assessment of A83B4C 63 prior to full-scale synthesis. The optimization work encompasses precursor synthesis refinement, process scale-up, and analytical method development in accordance with international quality standards to ensure a robust and reproducible manufacturing process suitable for future GM PNKP production. Annuncio • Oct 31
Onco-Innovations Limited Announces Board of Directors Changes Onco-Innovations Limited announced the appointment of Mr. Jared Rushton to its Board of Directors, effective 31 October 2025. Mr. Rushton brings over a decade of experience in the public markets, with a strong background in corporate development, strategic advisory, and capital markets planning. Throughout his career, he has worked closely with emerging and growth-stage companies to support financing initiatives, investor engagement, market positioning, and operational execution.
His diverse industry experience spans the mining, cannabis, and biotech and health sciences sectors, where he has played a key role in evaluating strategic opportunities, structuring partnerships, and guiding long-term growth strategies. Mr. Rushton has also advised on go-public transactions, corporate restructuring, and business development programs designed to enhance corporate value and strengthen shareholder alignment. Mr. Rushton replaces Mr. Zachary Stadnyk, who has stepped down from the Board. The Company extends its gratitude to Mr. Stadnyk for his dedication and contributions during his tenure. Annuncio • Oct 28
Onco-Innovations Limited announced that it has received CAD 1.999998 million in funding On October 27, 2028, Onco-Innovations Limited closed the transaction. The company announced that it has issued 1,428,570 units at a price of CAD 1.40 per Unit, for aggregate gross proceeds of CAD 1,999,998. Each Unit consists of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one Share at a price of CAD 2.00 for a period of thirty-six (36) months. In connection with the closing of the Private Placement, the Company paid, in aggregate, CAD 119,999.94 and issued 85,714 Warrants to certain finders in consideration for their introducing subscribers. The Company has also issued 14,286 Shares (“Administrative Shares”) of the Company to an arm’s-length third party, in consideration for administrative services rendered in connection with the Private Placement. Annuncio • Oct 15
Onco-Innovations Limited announced that it expects to receive CAD 2.000001 million in funding Onco-Innovations Limited announced a non-brokered private placement to issue 1,428,572 units at an issue price of CAD 1.40 for gross proceeds of CAD 2,000,000.8 on October 14, 2025. Each unit shall consist of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one share at an exercise price of CAD 2 for a period of thirty-six months. The company also intends to issue shares equal to 1% of the total of shares issued in the private placement to an arm’s-length third party, as an administrative fee for their assistance with the private placement. In connection with the private placement, the company may pay finders’ fees and/or issue finders’ warrants on the same terms as the warrants, to eligible parties who have assisted by introducing subscribers to the private placement. Closing of the private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. Annuncio • Sep 23
Onco Innovations Appoints Michael Lock to Scientific & Clinical Advisory Board Onco-Innovations Limited announced the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco in its development of novel therapies, including its PNKP inhibitor program. Dr. Lock is a Professor at Western University in the Department of Oncology and the Department of Medical Biophysics. He is a staff radiation oncologist who trained at Princess Margaret Hospital, University of Toronto, McMaster University, and the University of Wisconsin. Over his career, he has held leadership roles as Chair of the Department of Radiation Oncology, Chief of Division of Radiation Oncology, Medical Director of the London Regional Cancer Program, and Southwest Regional Radiation Oncology Lead. His experience spans clinical operations, trial oversight, and strategic program development across multiple oncology subspecialties. He has chaired and co-chaired several multidisciplinary site teams, including Breast Cancer, Genitourinary, and Hepatobiliary programs, ensuring integration of clinical research into patient care. Dr. Lock also served as Chair of the Radiation Oncology Provincial Advisory Committee, where he helped shape provincial priorities that established protocols and infrastructure that will serve patients for many years to come. He is an Associate Scientist with the Lawson Health Research Institute. His leadership in clinical trial methodology, coupled with his ability to align diverse research teams, will be highly relevant to Onco's translational and clinical pipeline. In addition to his work in Canada, Dr. Lock has contributed to advancing cancer care globally through collaborations with the International Atomic Energy Agency (IAEA), the United Nations (UN), and the World Health Organization (WHO). He has received multiple recognitions, including the Human Touch Award and the MAC Administrative Award, for his leadership and contributions to oncology. Annuncio • Sep 06
Onco-Innovations Limited Announces the Appointment of Dr. John Mackey to Its Scientific and Clinical Advisory Board Onco-Innovations Limited announce the appointment of Dr. John Mackey, Professor Emeritus in the Department of Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. His expertise will support Onco's efforts in aligning translational research with clinical execution, particularly as the Company progresses toward later-stage development of its PNKP inhibitor program. Dr. Mackey has extensive experience in oncology, clinical trials, and cancer drug development. He previously served as Director of the Clinical Trial Unit at the Cross Cancer Institute and as Executive Director of Translational Research in Oncology (TRIO), a not-for-profit academic clinical research organization responsible for interventional cancer trials involving more than 22,000 participants1 globally. He is a co-founder of Pacylex Pharmaceuticals, a biotechnology company developing therapies targeting N-myristoyl transferases, currently in Phase II international trials. He is also the CEO of illumiSonics, which is developing Microcellular Laser Imaging (MLI) technology for molecular histology. Additional initiatives include founding SMHeartCard, a personal emergency medication carriage system, and co-developing CWTA, a statistical method for analyzing multiple health states in clinical trials. Across these ventures, Dr. Mackey has been directly involved in advancing novel therapies from early-stage development through to clinical evaluation and commercialization, providing relevant experience for Onco's translational and commercial ambitions. Dr. Mackey holds 12 patents and has co-authored over 300 peer-reviewed publications covering a range of topics, including membrane transporter biochemistry, oncology clinical trials, cancer diagnostics, physical activity as an intervention for cancer patients, and statistical methodologies. He is a Fellow of the Canadian Academy of Health Sciences. In his role on the Scientific &Clinical Advisory Board, Dr. Mackey will contribute his expertise in clinical development, trial methodology, and translational oncology. His responsibilities will include advising on clinical strategy related to the Company's PNKP Inhibitor Technology (NP/A83) and other ongoing research programs. Board Change • Aug 18
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Maximilian Justus is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Aug 14
Onco-Innovations Limited announced that it has received CAD 0.400001 million in funding On August 13, 2025. Onco-Innovations Limited announced that it has closed the transaction. It has issued 243,903 units at a price of CAD 1.64 per unit for proceeds of CAD 400,000.92. Annuncio • Jul 30
Onco-Innovations Limited announced that it expects to receive CAD 0.400001 million in funding Onco-Innovations Limited announces a non-brokered private placement to issue 243,903 units at a price of CAD 1.64 per unit for gross proceeds of CAD 400,000.92 on July 29, 2025. Each Unit shall consist of one common share and one Share purchase warrant, with each Warrant entitling the holder to purchase one Share at an exercise price of CAD 2.05 for a period of 36 months. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. Annuncio • Jul 11
Onco-Innovations Limited Announces Appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory Board Onco-Innovations Limited announced the appointment of Dr. Islam Mohamed as Chair of Its Scientific and Clinical Advisory Board. This appointment reflects the Company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research. Dr. Islam Mohamed is an experienced Radiation Oncologist, clinical researcher, and biotechnology advisor who has spent over two decades operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he pursued a career in Medicine, completing his specialty training in Radiation Oncology in 2000. At BC Cancer, he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, and is recognized for his expertise in stereotactic radiation delivery. Dr. Mohamed has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. He has also served on research ethics boards and national clinical trial committees, shaping standards of care and clinical research strategy in Canada. Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem. He advises and invests in emerging Canadian biotech ventures, including Linax Technologies, IllumiSonics, and Asep Medical, with a focus on companies developing transformative diagnostics, therapeutics, and platform technologies. His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation. The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development (R&D) priorities. Its mandate is to provide strategic guidance on R&D initiatives, facilitate clinical and scientific collaboration among partners, and support the mobilization of knowledge and generation of independent scientific insights to guide decision-making. Annuncio • Jun 17
Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025 Onco-Innovations Limited, Annual General Meeting, Aug 12, 2025. Annuncio • May 01
Onco-Innovations Limited announced that it has received CAD 0.6 million in funding On April 30, 2025 Onco-Innovations Limited closed the transaction and issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase one share at an exercise price of CAD 1.60 for a period of 36 months expiring April 30, 2028. The company has also issued 4,000 shares at a deemed price of CAD 1.50 per administrative share of the company to an arm's-length third party in consideration for administrative services rendered in connection with the private placement. Pursuant to applicable securities laws, all securities issued under the private placement and the administrative shares will be subject to a statutory hold period of four months and one day, expiring on Aug. 31, 2025. Annuncio • Apr 17
Onco-Innovations Limited announced that it expects to receive CAD 0.6 million in funding Onco-Innovations Limited announced a non-brokered private placement to issue 400,000 units at an issue price of CAD 1.50 per unit for gross proceeds of CAD 600,000 on April 16, 2025. Each Unit shall consist of one common share and one common share purchase warrant, with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of CAD 1.60 for a period of 36 months. Closing of the Private Placement is anticipated to occur on or about April 25, 2025, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. Annuncio • Feb 04
Onco-Innovations Limited (CNSX:ONCO) completed the acquisition of acquire Inka Health Corp. Onco-Innovations Limited (CNSX:ONCO) signed a letter of intent to acquire Inka Health Corp. for CAD 3 million on January 22, 2025. Consideration consists of common shares of the Onco-Innovations Limited as are equal to CAD 3 million. The transaction is subject to consummation of due diligence investigation.
Onco-Innovations Limited (CNSX:ONCO) completed the acquisition of acquire Inka Health Corp. on February 3, 2025. As part of consideration issued 1,775,147 common shares of Onco-Innovations Limited. Annuncio • Jan 28
Onco-Innovations Limited announced that it expects to receive CAD 1.000002 million in funding Onco-Innovations Limited announced a non-brokered private placement to issue 408,164 units at issue price of CAD 2.45 per unit for gross proceeds of CAD 1,000,001.8 on January 27, 2025. Each Unit shall consist of one common share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one Share at an exercise price of CAD 2.55 for a period of 24 months from the date of issuance. Closing of the Private Placement is anticipated to occur on or about January 31, 2025. Closing is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to the Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. Annuncio • Jan 23
Onco-Innovations Limited (CNSX:ONCO) signed a letter of intent to acquire Inka Health Corp. for CAD 3 million. Onco-Innovations Limited (CNSX:ONCO) signed a letter of intent to acquire Inka Health Corp. for CAD 3 million on January 22, 2025. Consideration consists of common shares of the Onco-Innovations Limited as are equal to CAD 3 million. The transaction is subject to consummation of due diligence investigation. Annuncio • Jan 09
Onco-Innovations Limited Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options Onco-Innovations Limited provided information on its exclusively-licensed PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors technology (the ‘Technology’), which the Company believes holds the potential to significantly enhance the effectiveness of several cancer treatment options across a broad spectrum of cancer types including colorectal cancer (CRC), breast cancer and lung cancer. This Technology targets cancer cells to effectively eliminate them. It also prevents DNA repair in cancer cells. Unlike conventional cancer therapies, which often face challenges in accurately targeting tumours and overcoming resistance in certain cancer cells, Onco's exclusively-licensed Technology has demonstrated effectiveness both as a standalone treatment and in combination with radiation and chemotherapy. The Company considers this advanced delivery system to have the potential to make a significant impact in the rapidly expanding oncology market, which is projected to reach USD 521.60 billion globally and USD 180.12 billion in the U.S. by 2033. The Company believes this exclusively licensed Technology, once further developed, and contingent upon U.S. Federal Drug Administration (FDA) Phase 1 - 3 clinical trials being completed and approved, has the potential to both capture market share and address the pressing challenges that conventional cancer treatments have struggled to overcome. Traditional cancer treatments face significant limitations, such as the inability to exclusively target tumours, resistance from subgroups of cancer cells, and challenges in reaching all affected cells during chemotherapy. Additionally, radiation therapy can leave behind hard-to-destroy cancer cells in low-oxygen environments, and some cells are able to repair their DNA after treatment, leading to potential recurrence. The Technology directly addresses these challenges, particularly with respect to common cancers like colorectal cancer, offering a novel approach that, it is hoped, will improve patient outcomes and provide a much-needed solution where traditional therapies have been less effective. 
